Koers Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE
Aandelen
TEVA
IL0006290147
Farmaceutische producten
Omzet 2024 * | 15,86 mld. 59,62 mld. 14,84 mld. | Omzet 2025 * | 16,35 mld. 61,43 mld. 15,29 mld. | Marktkapitalisatie | 14,74 mld. 55,38 mld. 13,79 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1,54 mld. 5,78 mld. 1,44 mld. | Nettowinst (verlies) 2025 * | 1,44 mld. 5,42 mld. 1,35 mld. | EV/omzet 2024 * | 1,85 x |
Nettoschuld 2024 * | 14,62 mld. 54,95 mld. 13,68 mld. | Nettoschuld 2025 * | 12,12 mld. 45,54 mld. 11,34 mld. | EV/omzet 2025 * | 1,64 x |
K/w-verhouding 2024 * |
10,4
x | K/w-verhouding 2025 * |
9,73
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,71% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 60 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+27,92% | 672 mld. | |
+26,76% | 570 mld. | |
-4,59% | 360 mld. | |
+16,38% | 321 mld. | |
+9,39% | 300 mld. | |
+7,36% | 217 mld. | |
+5,93% | 199 mld. | |
-8,26% | 204 mld. | |
-8,58% | 149 mld. |